These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 35737871)

  • 21. Emerging nanomedicine-based strategies for preventing metastasis of pancreatic cancer.
    Li YJ; Wu JY; Wang JM; Xiang DX
    J Control Release; 2020 Apr; 320():105-111. PubMed ID: 31978441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanomedicine strategies for sustained, controlled and targeted treatment of cancer stem cells.
    Gao J; Li W; Guo Y; Feng SS
    Nanomedicine (Lond); 2016 Dec; 11(24):3261-3282. PubMed ID: 27854161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nanomedicine: a new frontier in cancer therapeutics.
    Lee PY; Wong KK
    Curr Drug Deliv; 2011 May; 8(3):245-53. PubMed ID: 21291378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Minimally invasive nanomedicine: nanotechnology in photo-/ultrasound-/radiation-/magnetism-mediated therapy and imaging.
    Ouyang J; Xie A; Zhou J; Liu R; Wang L; Liu H; Kong N; Tao W
    Chem Soc Rev; 2022 Jun; 51(12):4996-5041. PubMed ID: 35616098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current nano-therapeutic approaches ameliorating inflammation in cancer progression.
    Rehman MU; Khan A; Imtiyaz Z; Ali S; Makeen HA; Rashid S; Arafah A
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):886-908. PubMed ID: 35143992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anticancer Nanotherapeutics in Clinical Trials: The Work behind Clinical Translation of Nanomedicine.
    Parodi A; Kolesova EP; Voronina MV; Frolova AS; Kostyushev D; Trushina DB; Akasov R; Pallaeva T; Zamyatnin AA
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanomedicines: Redefining traditional medicine.
    Lu W; Yao J; Zhu X; Qi Y
    Biomed Pharmacother; 2021 Feb; 134():111103. PubMed ID: 33338747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating Nanomedicines: Obstacles and Advancements.
    Swierczewska M; Crist RM; McNeil SE
    Methods Mol Biol; 2018; 1682():3-16. PubMed ID: 29039088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The importance of reflecting on treatment and post-treatment care when assessing the social aspects of cosmetic nanomedicine and transdermal delivery system.
    Duché G; Thordarson P; Kearnes M
    Nanomedicine; 2020 Aug; 28():102214. PubMed ID: 32360550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanodelivery systems for improved topical antimicrobial therapy.
    Basnet P; Škalko-Basnet N
    Curr Pharm Des; 2013; 19(41):7237-43. PubMed ID: 23489202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanoparticles for imaging and treatment of metastatic breast cancer.
    Mu Q; Wang H; Zhang M
    Expert Opin Drug Deliv; 2017 Jan; 14(1):123-136. PubMed ID: 27401941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted Protein Degradation Technology and Nanomedicine: Powerful Allies against Cancer.
    Lin JY; Liu HJ; Wu Y; Jin JM; Zhou YD; Zhang H; Nagle DG; Chen HZ; Zhang WD; Luan X
    Small; 2023 May; 19(18):e2207778. PubMed ID: 36693784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The potential role of nano- and micro-technology in the management of critical illnesses.
    Sadikot RT
    Adv Drug Deliv Rev; 2014 Nov; 77():27-31. PubMed ID: 25204519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nanotechnology for nanomedicine and delivery of drugs.
    Venugopal J; Prabhakaran MP; Low S; Choon AT; Zhang YZ; Deepika G; Ramakrishna S
    Curr Pharm Des; 2008; 14(22):2184-200. PubMed ID: 18781971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nanomedicine of tyrosine kinase inhibitors.
    Smidova V; Michalek P; Goliasova Z; Eckschlager T; Hodek P; Adam V; Heger Z
    Theranostics; 2021; 11(4):1546-1567. PubMed ID: 33408767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthetic Lethality: From Research to Precision Cancer Nanomedicine.
    Gupta A; Ahmad A; Dar AI; Khan R
    Curr Cancer Drug Targets; 2018; 18(4):337-346. PubMed ID: 28669337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications.
    Ranganathan R; Madanmohan S; Kesavan A; Baskar G; Krishnamoorthy YR; Santosham R; Ponraju D; Rayala SK; Venkatraman G
    Int J Nanomedicine; 2012; 7():1043-60. PubMed ID: 22403487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor-targeted nanomedicines for cancer theranostics.
    Arranja AG; Pathak V; Lammers T; Shi Y
    Pharmacol Res; 2017 Jan; 115():87-95. PubMed ID: 27865762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanomedical engineering: shaping future nanomedicines.
    Luo D; Carter KA; Lovell JF
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2015; 7(2):169-88. PubMed ID: 25377691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanotechnological strategies for therapeutic targeting of tumor vasculature.
    Ding Y; Li S; Nie G
    Nanomedicine (Lond); 2013 Jul; 8(7):1209-22. PubMed ID: 23837858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.